OncoImmunology,
Journal Year:
2025,
Volume and Issue:
14(1)
Published: May 22, 2025
The
annual
ImmunoRad
Conference
has
established
itself
as
a
recurrent
occasion
to
explore
the
possibility
of
combining
radiation
therapy
(RT)
and
immunotherapy
(IT)
for
clinical
cancer
management.
Bringing
together
number
preclinical
leaders
in
fields
oncology,
immuno-oncology
IT,
this
event
fosters
indeed
essential
conversations
fruitful
exchanges
on
how
address
existing
challenges
expand
therapeutic
value
RT-IT
combinations.
8th
edition
Conference,
which
been
held
October
2024
at
Weill
Cornell
Medical
College
New
York
City,
highlighted
exciting
advances
interface
between
RT
setting
stage
extra
progress
toward
extended
benefits
patients
with
an
increasing
variety
tumor
types.
Here,
we
critically
summarize
lines
investigation
that
have
discussed
Annual
Conference.
Journal of Advanced Research,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
After
significant
advancements
in
tumor
treatment,
personalized
cell
therapy
based
on
chimeric
antigen
receptors
(CAR)
holds
promise
for
transforming
the
management
of
various
diseases.
CAR-T
therapy,
first
approved
CAR
product,
has
demonstrated
therapeutic
potential
treating
infectious
diseases,
autoimmune
disorders,
and
fibrosis.
CAR-macrophages
(CAR-Ms)
are
emerging
as
a
promising
approach
immune
particularly
solid
highlighting
feasibility
using
macrophages
to
eliminate
pathogens
abnormal
cells.
Biomolecules,
Journal Year:
2025,
Volume and Issue:
15(3), P. 378 - 378
Published: March 5, 2025
Antiretroviral
therapy
(ART)
can
effectively
suppress
the
replication
of
human
immunodeficiency
virus
(HIV),
but
it
cannot
completely
eradicate
virus.
The
persistent
existence
HIV
reservoir
is
a
major
obstacle
in
quest
for
cure.
To
date,
there
have
been
total
seven
cured
cases
worldwide.
These
patients
all
cleared
while
undergoing
allogeneic
stem
cell
transplantation
(allo-HSCT)
hematological
malignancies.
However,
these
cases,
specific
mechanism
by
which
allo-HSCT
leads
to
eradication
remains
unclear,
so
necessary
conduct
an
in-depth
analysis.
Due
difficulty
obtaining
donors
and
risks
associated
with
transplantation,
this
treatment
method
not
applicable
patients.
There
still
need
explore
new
strategies.
In
recent
years,
emerging
therapies
such
as
neutralizing
antibody
immunotherapy,
chimeric
antigen
receptor
T
(CAR-T)
therapy,
gene
editing,
antiviral
targeting
attracted
wide
attention
due
their
ability
inhibit
replication.
This
article
first
elaborates
on
nature
reservoir,
then
deeply
explores
modalities
potential
success
factors
finally
discusses
current
novel
methods,
hoping
provide
comprehensive
feasible
strategies
achieving
cure
HIV.
Discover Oncology,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: April 8, 2025
The
DNA
damage
response
(DDR)
has
a
major
impact
on
the
development
and
progression
of
pancreatic
ductal
adenocarcinoma
(PDAC).
Investigating
biomarkers
linked
to
DDR
may
facilitate
prognostic
assessment
prediction
immunological
characteristics
for
patients
with
PDAC.
single-cell
RNA
sequencing
(scRNA-seq)
dataset
GSE212966
was
obtained
from
GEO
database,
whereas
bulk
RNA-seq
data
were
sourced
Cancer
Genome
Atlas
(TCGA)
Genotype-Tissue
Expression
(GTEx)
databases.
Least
absolute
shrinkage
selection
operator
(LASSO)
univariate
Cox
regression
analyses
used
select
genes
construct
risk
model.
Finally,
correlations
model
score
drug
sensitivity,
checkpoints,
immune
infiltration
assessed.
We
16
marker
predictive
Furthermore,
we
established
that
had
strong
performance
in
both
training
validation
cohorts.
For
PDAC,
served
as
an
independent
predictor
prognosis.
There
notable
differences
proportions
cells
tumor
microenvironment
sensitivity
between
high
low
groups.
study
confirmed
is
useful
predicting
immunotherapy
response.
Our
experiments
verified
knockdown
LY6D
inhibits
cell
proliferation,
promotes
apoptosis
damage.
creative
integration
scRNA-seq
allowed
us
DDR-related
can
be
predict
features,
treatment
prognosis
PDAC
relatively
degree
accuracy.
The Journal of Immunology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 10, 2025
Abstract
Chimeric
antigen
receptor
T
(CART)
cell
therapy
is
an
innovative
form
of
immunotherapy
that
has
shown
remarkable
and
long-term
responses
in
patients
with
B-cell
malignancies.
Over
the
years,
field
made
significant
progress
our
understanding
successes
challenges
associated
CART
therapy.
In
this
review,
we
provide
overview
current
state
clinic.
We
detail
including
patient
access,
CART-associated
toxicity,
tumor
heterogeneity,
trafficking,
microenvironment,
different
fates.
With
each
challenge,
review
lessons
learned,
potential
solutions
outline
areas
for
future
development.
Finally,
discuss
how
engineered
moving
into
treatment
solid
tumors
other
diseases
beyond
cancer.
Advanced Healthcare Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 6, 2025
Abstract
Chemodynamic
therapy
(CDT)
holds
great
promise
in
cancer
treatment,
whereas
its
efficacy
is
severely
compromised
by
the
low
concentration
of
endogenous
hydrogen
peroxide(H
2
O
),
insufficient
exogenous
catalytic
ions,
and
presence
high
levels
cellular
glutathione
(GSH).
Herein,
a
dissociable,
tumor
cell
membrane‐camouflaged
carrier‐free
nanoparticle
developed
through
molecular
interaction
copper
ions
(Cu
2+
dequalinium
(DQ),
β‐Lapachone
(β‐Lap).
Upon
homotypic
targeting,
system
releases
Cu
(exogenous
ions),
β‐Lap
(H
donor),
DQ
(GSH
scavenger),
achieving
triple
amplification
CDT
efficacy.
Concurrently,
intracellular
accumulation
induces
cuproptosis,
thereby
synergistically
augmenting
strikingly
restraining
growth.
Overall,
integration
supplementation,
H
self‐supplying,
GSH
depletion
offers
promising
avenue
for
improving
treatment
outcomes
paves
new
way
multimodal
therapy.
